Journal
JOURNAL OF NEUROSCIENCE
Volume 25, Issue 7, Pages 1769-1777Publisher
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.5207-04.2005
Keywords
Alzheimer's disease; hydroethidine; gp91(phox); Tg2576; cerebral blood flow; reactive oxygen species
Categories
Funding
- NHLBI NIH HHS [HL18974, P01 HL018974] Funding Source: Medline
- NIA NIH HHS [AG15453, P01 AG015453] Funding Source: Medline
- NINDS NIH HHS [NS38252] Funding Source: Medline
Ask authors/readers for more resources
Overproduction of the amyloid beta (Abeta) peptide is a key factor in the pathogenesis of Alzheimer's disease (AD), but the mechanisms of its pathogenic effects have not been defined. Patients with AD have cerebrovascular alterations attributable to the deleterious effects of Abeta on cerebral blood vessels. We report here that NADPH oxidase, the major source of free radicals in blood vessels, is responsible for the cerebrovascular dysregulation induced by Abeta. Thus, the free-radical production and the associated alterations in vasoregulation induced by Abeta are abrogated by the NADPH oxidase peptide inhibitor gp91ds-tat and are not observed in mice lacking the catalytic subunit of NADPH oxidase (gp91(phox)). Furthermore, oxidative stress and cerebrovascular dysfunction do not occur in transgenic mice overexpressing the amyloid precursor protein but lacking gp91phox. The mechanisms by which NADPH oxidase-derived radicals mediate the cerebrovascular dysfunction involve reduced bioavailability of nitric oxide. Thus, a gp91(phox)-containing NADPH oxidase is the critical link between Abeta and cerebrovascular dysfunction, which may underlie the alteration in cerebral blood flow regulation observed in AD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available